Logo image of ACTU

ACTUATE THERAPEUTICS INC (ACTU) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACTU - US0050831009 - Common Stock

6.43 USD
+0.18 (+2.88%)
Last: 11/26/2025, 12:59:55 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ACTU. ACTU was compared to 533 industry peers in the Biotechnology industry. ACTU has a bad profitability rating. Also its financial health evaluation is rather negative. ACTU has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACTU has reported negative net income.
In the past year ACTU has reported a negative cash flow from operations.
ACTU Yearly Net Income VS EBIT VS OCF VS FCFACTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

ACTU has a Return On Assets of -136.16%. This is amonst the worse of the industry: ACTU underperforms 83.30% of its industry peers.
Looking at the Return On Equity, with a value of -220.55%, ACTU is doing worse than 69.04% of the companies in the same industry.
Industry RankSector Rank
ROA -136.16%
ROE -220.55%
ROIC N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACTU Yearly ROA, ROE, ROICACTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -5K -10K -15K -20K -25K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACTU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACTU Yearly Profit, Operating, Gross MarginsACTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ACTU has been increased compared to 1 year ago.
Compared to 1 year ago, ACTU has an improved debt to assets ratio.
ACTU Yearly Shares OutstandingACTU Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
ACTU Yearly Total Debt VS Total AssetsACTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -2.97, we must say that ACTU is in the distress zone and has some risk of bankruptcy.
ACTU has a Altman-Z score of -2.97. This is comparable to the rest of the industry: ACTU outperforms 48.41% of its industry peers.
ACTU has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
ACTU has a Debt to Equity ratio of 0.04. This is comparable to the rest of the industry: ACTU outperforms 41.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -2.97
ROIC/WACCN/A
WACCN/A
ACTU Yearly LT Debt VS Equity VS FCFACTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 2.74 indicates that ACTU has no problem at all paying its short term obligations.
With a Current ratio value of 2.74, ACTU is not doing good in the industry: 66.23% of the companies in the same industry are doing better.
A Quick Ratio of 2.74 indicates that ACTU has no problem at all paying its short term obligations.
ACTU has a worse Quick ratio (2.74) than 64.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.74
ACTU Yearly Current Assets VS Current LiabilitesACTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.91% over the past year.
EPS 1Y (TTM)49.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.03% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.69%
EPS Next 2Y26.23%
EPS Next 3Y14.29%
EPS Next 5Y18.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACTU Yearly Revenue VS EstimatesACTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ACTU Yearly EPS VS EstimatesACTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACTU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACTU Price Earnings VS Forward Price EarningsACTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACTU Per share dataACTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ACTU's earnings are expected to grow with 14.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.23%
EPS Next 3Y14.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACTU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTUATE THERAPEUTICS INC

NASDAQ:ACTU (11/26/2025, 12:59:55 PM)

6.43

+0.18 (+2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)N/A N/A
Inst Owners48.96%
Inst Owner Change2.42%
Ins Owners4.11%
Ins Owner Change0%
Market Cap147.38M
Revenue(TTM)N/A
Net Income(TTM)-24.12M
Analysts82
Price Target25.5 (296.58%)
Short Float %2.56%
Short Ratio7.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.6%
Min EPS beat(2)3.52%
Max EPS beat(2)11.68%
EPS beat(4)2
Avg EPS beat(4)0.05%
Min EPS beat(4)-11.56%
Max EPS beat(4)11.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.54%
PT rev (3m)-13.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.19%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.48
P/tB 13.48
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.31
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -136.16%
ROE -220.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-405.72%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.74
Quick Ratio 2.74
Altman-Z -2.97
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.48%
EPS Next Y63.69%
EPS Next 2Y26.23%
EPS Next 3Y14.29%
EPS Next 5Y18.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y44.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.01%
OCF growth 3YN/A
OCF growth 5YN/A

ACTUATE THERAPEUTICS INC / ACTU FAQ

What is the fundamental rating for ACTU stock?

ChartMill assigns a fundamental rating of 1 / 10 to ACTU.


Can you provide the valuation status for ACTUATE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ACTUATE THERAPEUTICS INC (ACTU). This can be considered as Overvalued.


What is the profitability of ACTU stock?

ACTUATE THERAPEUTICS INC (ACTU) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ACTU stock?

The Earnings per Share (EPS) of ACTUATE THERAPEUTICS INC (ACTU) is expected to grow by 63.69% in the next year.